PURPOSE: Gastric fundoplication (GF) for gastroesophageal reflux disease (GERD) may protect against the progression of chronic rejection in lung transplant (LT) recipients. However, the association of GERD with acute rejection episodes (ARE) is uncertain. This study sought to identify if ARE were linked to GERD in LT patients. METHODS: This single-center retrospective observational study, of patients transplanted from January 1, 2000, to January 31, 2009, correlated results of pH probe testing for GERD with ARE (≥International Society for Heart and Lung Transplantation A1 or B1). We compared the rates of ARE among patients with GERD (DeMeester Score > 14.7) versus without GERD as number of ARE per 1,000 patient-days after LT. Patients undergoing GF prior to LT were excluded. RESULTS: The analysis included 60 LT subjects and 9,249 patient-days: 33 with GERD versus 27 without GERD. We observed 51 ARE among 60 LT recipients. The rate of ARE was highest among patients with GERD: 8.49 versus 2.58, an incidence density ratio (IDR) of 3.29 (P = .00016). Upon multivariate negative binomial regression modeling, only GERD was associated with ARE (IDR 2.15; P = .009). Furthermore, GERD was associated with multiple ARE (36.4% vs 0%; P < .0001) and earlier onset compared with patients without GERD: ARE proportion at 2 months was 0.55 versus 0.26 P = .004). CONCLUSION: In LT recipients, GERD was associated with a higher rate, multiple events, and earlier onset of ARE. The efficacy of GF to reduce ARE among patients with GERD needs further evaluation. 2010 Elsevier Inc. All rights reserved.
PURPOSE: Gastric fundoplication (GF) for gastroesophageal reflux disease (GERD) may protect against the progression of chronic rejection in lung transplant (LT) recipients. However, the association of GERD with acute rejection episodes (ARE) is uncertain. This study sought to identify if ARE were linked to GERD in LT patients. METHODS: This single-center retrospective observational study, of patients transplanted from January 1, 2000, to January 31, 2009, correlated results of pH probe testing for GERD with ARE (≥International Society for Heart and Lung Transplantation A1 or B1). We compared the rates of ARE among patients with GERD (DeMeester Score > 14.7) versus without GERD as number of ARE per 1,000 patient-days after LT. Patients undergoing GF prior to LT were excluded. RESULTS: The analysis included 60 LT subjects and 9,249 patient-days: 33 with GERD versus 27 without GERD. We observed 51 ARE among 60 LT recipients. The rate of ARE was highest among patients with GERD: 8.49 versus 2.58, an incidence density ratio (IDR) of 3.29 (P = .00016). Upon multivariate negative binomial regression modeling, only GERD was associated with ARE (IDR 2.15; P = .009). Furthermore, GERD was associated with multiple ARE (36.4% vs 0%; P < .0001) and earlier onset compared with patients without GERD: ARE proportion at 2 months was 0.55 versus 0.26 P = .004). CONCLUSION: In LT recipients, GERD was associated with a higher rate, multiple events, and earlier onset of ARE. The efficacy of GF to reduce ARE among patients with GERD needs further evaluation. 2010 Elsevier Inc. All rights reserved.
Authors: Matthew G Hartwig; James Z Appel; Bin Li; Chong-Chao Hsieh; Yong Han Yoon; Shu S Lin; William Irish; William Parker; R Duane Davis Journal: J Thorac Cardiovasc Surg Date: 2005-12-09 Impact factor: 5.209
Authors: Matthew P Sweet; Fernando A M Herbella; Lorriana Leard; Charles Hoopes; Jeffrey Golden; Steven Hays; Marco G Patti Journal: Ann Surg Date: 2006-10 Impact factor: 12.969
Authors: Matthew P Sweet; Marco G Patti; Lorriana E Leard; Jeffrey A Golden; Steven R Hays; Charles Hoopes; Pierre R Theodore Journal: J Thorac Cardiovasc Surg Date: 2007-02-22 Impact factor: 5.209
Authors: G Raghu; T D Freudenberger; S Yang; J R Curtis; C Spada; J Hayes; J K Sillery; C E Pope; C A Pellegrini Journal: Eur Respir J Date: 2006-01 Impact factor: 16.671
Authors: Susan Stewart; Michael C Fishbein; Gregory I Snell; Gerald J Berry; Annette Boehler; Margaret M Burke; Alan Glanville; F Kate Gould; Cynthia Magro; Charles C Marboe; Keith D McNeil; Elaine F Reed; Nancy L Reinsmoen; John P Scott; Sean M Studer; Henry D Tazelaar; John L Wallwork; Glen Westall; Martin R Zamora; Adriana Zeevi; Samuel A Yousem Journal: J Heart Lung Transplant Date: 2007-12 Impact factor: 10.247
Authors: Andres Pelaez; G Marshall Lyon; Seth D Force; Allan M Ramirez; David C Neujahr; Marianne Foster; Priyumvada M Naik; Anthony A Gal; Patrick O Mitchell; E Clinton Lawrence Journal: J Heart Lung Transplant Date: 2009-01 Impact factor: 10.247
Authors: K Blondeau; V Mertens; B A Vanaudenaerde; G M Verleden; D E Van Raemdonck; D Sifrim; L J Dupont Journal: Eur Respir J Date: 2007-12-05 Impact factor: 16.671
Authors: Rachel Stovold; Ian A Forrest; Paul A Corris; Desmond M Murphy; Jaclyn A Smith; Sam Decalmer; Gail E Johnson; John H Dark; Jeffrey P Pearson; Chris Ward Journal: Am J Respir Crit Care Med Date: 2007-04-05 Impact factor: 21.405
Authors: Geert M Verleden; Lieven Dupont; Jonas Yserbyt; Veronique Schaevers; Dirk Van Raemdonck; Arne Neyrinck; Robin Vos Journal: J Thorac Dis Date: 2017-09 Impact factor: 2.895
Authors: S Samuel Weigt; Ariss DerHovanessian; W Dean Wallace; Joseph P Lynch; John A Belperio Journal: Semin Respir Crit Care Med Date: 2013-07-02 Impact factor: 3.119
Authors: Chen Yang Kevin Zhang; Musawir Ahmed; Ella Huszti; Liran Levy; Sarah E Hunter; Kristen M Boonstra; Sajad Moshkelgosha; Andrew T Sage; Sassan Azad; Rasheed Ghany; Jonathan C Yeung; Oscar M Crespin; Lianne G Singer; Shaf Keshavjee; Tereza Martinu Journal: Respir Res Date: 2022-08-26
Authors: Ashwini Arjuna; Michael T Olson; Rajat Walia; Ross M Bremner; Michael A Smith; Thalachallour Mohanakumar Journal: Expert Rev Respir Med Date: 2020-10-25 Impact factor: 3.772